RPG Life Sciences Ltd
Healthcare | Small Cap
RPG Life Sciences Ltd presents a mixed but generally strong financial profile, marked by exceptional profitability and solvency. The company operates with virtually no debt, making it highly stable and resilient to economic downturns. It excels at generating profits from its sales and provides high returns to its investors. This financial strength is a significant positive. However, there are notable weaknesses. The company's operational efficiency is a concern, as it struggles to generate sales effectively from its large asset base. Furthermore, while sales are growing, profits have been declining, suggesting that the costs of growth are currently outweighing the benefits. The company's ability to meet immediate financial obligations is strong on paper, but cash generation from operations is a weaker point. The future outlook depends on its ability to translate its market growth and asset expansion into bottom-line profitability by improving operational efficiency.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.80
- Financial Ratio8.40
- Profitability Ratio10.00
- Efficiency Ratio4.67
- Coverage Ratio7.60
- Solvency Ratio10.00
- Liquidity Ratio7.88
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthBullish
RPG Life Sciences Ltd presents a mixed but generally strong financial profile, marked by exceptional profitability and solvency. The company operates with virtually no debt, making it highly stable and resilient to economic downturns. It excels at generating profits from its sales and provides high returns to its investors. This financial strength is a significant positive. However, there are notable weaknesses. The company's operational efficiency is a concern, as it struggles to generate sales effectively from its large asset base. Furthermore, while sales are growing, profits have been declining, suggesting that the costs of growth are currently outweighing the benefits. The company's ability to meet immediate financial obligations is strong on paper, but cash generation from operations is a weaker point. The future outlook depends on its ability to translate its market growth and asset expansion into bottom-line profitability by improving operational efficiency.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
32.70
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
32.70
P/B RATIO
6.22
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
5.31
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
20.34
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2277.4 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤29th Apr 26
Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
The company's growth profile is highly contradictory. On one hand, it is expanding its asset base and growing its revenues, which indicates positive business momentum and investment in future expansion. However, this top-line growth is not translating into profits. Key profitability indicators like operating profit, net income, and earnings per share are showing significant declines. This alarming trend suggests that the costs associated with growth are currently eroding profitability, pointing to potential inefficiencies or margin pressures.
| Growth Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue Growth Rate | 8.42 | |
| Operating Profit Growth Rate | -8.12 | |
| Earnings Per Share (EPS) Growth | -37.14 | |
| Asset Growth Rate | 20.52 | |
| Net Income Growth Rate | -37.16 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company demonstrates excellent financial strength from a shareholder's perspective, delivering high value in terms of earnings, cash flow, and dividends per share. The intrinsic book value per share is also very robust, indicating a solid asset backing. The one area of potential concern is the level of capital expenditure, which is high. While this represents investment for growth, it may also be contributing to the inefficiencies and lack of profit growth seen in other parts of the business.
| Financial Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 72.84 | 69.14 |
| Cash Earnings Per Share (Cash EPS) | 125.93 | 83.95 |
| Book Value Per Share | 327.16 | 373.46 |
| Dividend Per Share (DPS) | 0 | 23.68 |
| Capital Expenditures (CapEx) | 73 | 65 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is exceptional across the board. It demonstrates a superior ability to convert revenue into actual profit at every stage. Margins are very healthy, and the returns generated on the capital invested by both shareholders and lenders are outstanding. This indicates a highly effective business model, strong pricing power, and excellent cost control. This level of profitability is the company's primary strength and a very positive sign for investors.
| Profitability Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Gross Profit Margin | 21.29 | 17.8 |
| Return on Capital Employed (ROCE) | 44.15 | 26 |
| Return on Equity (ROE) | 34.53 | 19.01 |
| Return on Assets (ROA) | 24.32 | 18.54 |
| Operating Margin | 24.5 | 20.76 |
| Net Margin | 28.02 | 16.24 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's overall operational efficiency presents a mixed to weak picture. While it is quite effective at collecting payments from its customers, it struggles significantly in other key areas. The company is not effectively using its fixed assets or its total capital to generate sales revenue. Furthermore, it is relatively slow in selling its inventory. These inefficiencies suggest that there are operational bottlenecks that could be limiting the company's growth and profitability potential.
| Efficiency Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Fixed Asset Turnover Ratio | 3.55 | 3.54 |
| Inventory Turnover Ratio | 5.54 | 5.35 |
| Receivables Turnover Ratio | 7.6 | 6.94 |
| Days Sales in Inventory Ratio | 65.88 | 68.22 |
| Receivable Days | 48 | 52.59 |
| Capital Turnover Ratio | 1.23 | 1.15 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations is strong in some areas but weak in others. Its capacity to meet interest payments on debt is outstanding, largely because it has very little debt to begin with. This reflects very low financial risk. In contrast, its ability to cover dividend payments from its earnings is weak. This suggests that the current level of dividends could be unsustainable if the company's profits continue to decline.
| Coverage Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Interest Coverage Ratio | 234 | 155 |
| Equity Dividend Coverage Ratio | 2.94 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is exceptionally strong. It operates with almost no reliance on debt financing, indicating an extremely low level of financial risk. The business is funded almost entirely by owner's equity, which makes it very stable and not vulnerable to rising interest rates or credit market tightening. This conservative financial structure is a major strength and points to excellent long-term viability and financial independence.
| Solvency Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Debt Ratio | 0 | 0.02 |
| Debt to Equity Ratio | 0 | 0.02 |
| Equity Ratio | 1 | 0.98 |
| Debt To Asset Ratio | 0 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company shows a strong capacity to meet its short-term financial obligations using its available assets. It holds a healthy amount of cash and other liquid assets, which provides a solid safety net against immediate financial pressures. This indicates good management of current assets. A point of weakness, however, is its ability to generate sufficient cash from its core business operations to cover these same short-term debts. This suggests that while the balance sheet looks liquid, the operational cash flow is less robust.
| Liquidity Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Current Ratio | 2.7 | 2.79 |
| Quick Ratio | 1.97 | 2.08 |
| Cash Ratio | 1.1 | 1.1 |
| Operating Cash Flow Ratio | 0.61 | 0.32 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 4 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 5 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 6 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 7 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 8 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 9 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 10 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 11 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 12 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 13 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 14 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 15 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 16 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
| 18 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
Management effectiveness presents a mixed profile. The company demonstrates excellent financial prudence, maintaining a virtually debt-free balance sheet with outstanding interest coverage. Capital efficiency is strong, evidenced by high ROCE and ROE, and the ownership structure reflects confidence with high promoter holding and growing DII interest. However, these strengths are counterbalanced by significant operational weaknesses. The company is experiencing negative profit growth, declining profit margins, and increased volatility in quarterly earnings. Furthermore, working capital management has deteriorated, as shown by a worsening cash conversion cycle. This contrast between strong financial health and weakening core performance results in a mixed assessment. | Category | Metric | Value | Assessment | |---|---|---|---| | PROS | ROCE | 26% | Strong capital efficiency | | | Debt to Equity Ratio | 0.03 | Negligible financial leverage | | | DII Holding Trend | +7.34% (3Y) | Increasing institutional confidence | | CONS | TTM Profit Growth | -5% | Declining profitability | | | Cash Conversion Cycle | 99 Days | Worsening working capital efficiency | | | Operating Profit Margin | 21% | Contracting core margins |
Financial Performance & Growth
The company's financial performance shows signs of stress despite moderate sales growth. While Trailing Twelve Months (TTM) sales grew by 8%, this has not translated into profitability. Compounded profit growth for the TTM period is negative at -5%, and the annual profit for Mar 2026 also shows a 5% decline. This indicates a significant issue with converting revenue into profit. The Operating Profit Margin (OPM) has also contracted from 24% in Mar 2025 to 21% in Mar 2026. Quarterly performance is volatile; for instance, YOY profit growth was -18.32% in Dec 2025 but swung to 33.70% in Mar 2026, highlighting earnings inconsistency. The core net profit margin, based on annual profit excluding exceptional items, also declined from 18.1% in Mar 2025 to 15.8% in Mar 2026, questioning the strength of core operations. | Metric | Mar 2025 | Mar 2026 | TTM | |---|---|---|---| | Sales Growth (%) | | 8.28% | 8% | | Profit Growth (%) | | -5% | -5% | | OPM (%) | 24% | 21% | - | | Core NPM (Annual) (%) | 18.1% | 15.8% | - |
Capital Efficiency & Returns
Management has demonstrated strong capabilities in generating returns from its capital base. The company reports an excellent Return on Capital Employed (ROCE) of 26% for Mar 2026 and a Return on Equity (ROE) of 20.3%, indicating productive use of both debt and equity capital. However, recent trends in working capital management are concerning. The Cash Conversion Cycle (CCC) has deteriorated significantly, increasing from 72 days in Mar 2025 to 99 days in Mar 2026. This is driven by an increase in both Debtor Days (from 48 to 60) and Inventory Days (from 159 to 179), suggesting inefficiencies in collecting receivables and managing stock. Additionally, the asset turnover ratio has seen a slight decline from 0.99 to 0.89, indicating that assets are being converted into revenue less effectively than in the previous year. | Metric | Mar 2025 | Mar 2026 | |---|---|---| | ROCE (%) | - | 26% | | ROE (%) | 22.2% | 20.3% | | Cash Conversion Cycle (Days) | 72 | 99 | | Asset Turnover Ratio | 0.99 | 0.89 |
Financial Health & Prudence
The company's financial health is exceptionally strong. The balance sheet is robust, with a negligible debt-to-equity ratio of 0.03 as of Mar 2026. The company was virtually debt-free in Mar 2025 and has only taken on a small amount of borrowing (₹20 Cr) in the latest year, which is insignificant relative to its equity base of ₹605 Cr. This low leverage translates into a very high Interest Coverage Ratio of 147 times, meaning operating profits can comfortably cover interest obligations many times over. The company also maintains a healthy Dividend Payout ratio of 34% in Mar 2026. The Enterprise Value is primarily driven by its market capitalization rather than debt, underscoring the company's solid financial foundation and minimal financial risk. | Metric | Mar 2025 | Mar 2026 | |---|---|---| | Borrowings (Cr) | 0 | 20 | | Debt/Equity Ratio | 0.00 | 0.03 | | Interest Coverage Ratio | 160 | 147 | | Dividend Payout (%) | 0% | 34% |
Shareholding & Ownership Structure
The shareholding structure signals strong confidence from both promoters and institutional investors. Promoter holding is high and stable, standing at 72.95% in Mar 2026. This figure has remained consistently above 72% for several years. More notably, there has been a sharp and sustained increase in Domestic Institutional Investor (DII) holding. DIIs have increased their stake from a mere 0.11% in Mar 2023 to 7.45% in Mar 2026, demonstrating growing confidence from sophisticated domestic investors. While Foreign Institutional Investor (FII) holding has been more volatile, it has also seen a general upward trend over the long term. This strong ownership profile, characterized by high promoter conviction and rising institutional participation, is a significant strength. | Shareholding (%) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |---|---|---|---|---|---| | Promoters | 72.07% | 72.82% | 72.82% | 72.95% | 72.95% | | FIIs | 0.12% | 0.38% | 0.90% | 1.46% | 0.87% | | DIIs | 0.01% | 0.11% | 2.16% | 6.14% | 7.45% |
The overall risk assessment is driven primarily by concerns regarding accounting quality and earnings predictability. The frequent use of large and volatile 'Exceptional Items' significantly distorts the reported net profit, making it difficult to assess the company's core operational performance. This lack of earnings transparency is a key risk. While the company's financial risk is very low due to its negligible debt and strong balance sheet, the operational risks are rising, as evidenced by declining margins and deteriorating working capital metrics. The combination of low financial risk but higher operational and accounting-related risks justifies a moderate risk rating.
Accounting Quality
A significant red flag is the high volatility and magnitude of 'Exceptional items' in its profit and loss statements. These items obscure the true underlying performance of the core business. In the Mar 2025 quarter, the reported Net Profit of ₹117 Cr was heavily inflated by a positive exceptional item of ₹95.6 Cr. In contrast, the Dec 2025 quarter included a negative exceptional item of ₹6.4 Cr. This inconsistency makes year-on-year and quarter-on-quarter comparisons of reported profitability unreliable. The sheer size and frequency of these adjustments create uncertainty and reduce the overall quality and predictability of earnings. | Metric (₹ Cr) | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |---|---|---|---|---| | Net Profit | 117.35 | 36.85 | 22.13 | 29.90 | | Exceptional items AT | 95.60 | 8.36 | -6.40 | 0.82 | | Profit excl Excep | 21.75 | 28.49 | 28.53 | 29.08 |
Operational Performance
Operational risks are increasing, reflected in deteriorating efficiency and profitability metrics. The Cash Conversion Cycle has worsened from 72 days to 99 days in a single year, indicating growing pressure on working capital. This is a result of both slower receivables collection (Debtor Days up from 48 to 60) and longer inventory holding periods (Inventory Days up from 159 to 179). Simultaneously, core profitability is under pressure, with the annual Operating Profit Margin (OPM) contracting from 24% to 21%. This combination of declining margins and weakening working capital management signals rising operational challenges. | Metric | Mar 2025 | Mar 2026 | Trend | |---|---|---|---| | Cash Conversion Cycle (Days) | 72 | 99 | Deteriorating | | Operating Profit Margin (%) | 24% | 21% | Declining | | Asset Turnover Ratio | 0.99 | 0.89 | Declining |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102284.47Bullish
- SMA 202292.73Bullish
- SMA 502269.20Bullish
- EMA 102289.23Bullish
- EMA 202286.51Bullish
- EMA 502263.35Bullish
- DEMA 102291.63Bullish
- DEMA 202295.54Bullish
- DEMA 502298.67Bullish
- TEMA 102295.21Bullish
- TEMA 202286.35Bullish
- TEMA 502316.87Bullish
- MACD5.97Bearish
- ADX23.74Weak Trend
- IndicatorValueSignal
- RSI63.99Neutral
- CCI60.94Neutral
- ROC 91.28Bullish
- ROC 140.67Bullish
- ROC 251.04Bullish
- Stoch K50.18Neutral
- Stoch D37.09Neutral
- IndicatorValueSignal
- BB Upper2320.74Neutral
- BB Middle2292.73Neutral
- BB Lower2264.73Neutral
- ATR21.22High Volatility
- IndicatorValueSignal
- MFI35.22Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102289.37Bullish
- SMA 202290.69Bullish
- SMA 502210.75Bullish
- EMA 102289.41Bullish
- EMA 202275.63Bullish
- EMA 502244.67Bullish
- DEMA 102297.58Bullish
- DEMA 202306.29Bullish
- DEMA 502268.14Bullish
- TEMA 102293.31Bullish
- TEMA 202306.69Bullish
- TEMA 502293.54Bullish
- MACD21.04Bearish
- ADX41.97Strong Trend
- IndicatorValueSignal
- RSI63.37Neutral
- CCI72.98Neutral
- ROC 90.66Bullish
- ROC 141.58Bullish
- ROC 255.47Bullish
- Stoch K49.58Neutral
- Stoch D36.82Neutral
- IndicatorValueSignal
- BB Upper2322.08Neutral
- BB Middle2290.68Neutral
- BB Lower2259.29Neutral
- ATR32.52High Volatility
- IndicatorValueSignal
- MFI46.51Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102290.83Bullish
- SMA 202221.44Bullish
- SMA 502232.81Bullish
- EMA 102276.67Bullish
- EMA 202250.61Bullish
- EMA 502225.68Bullish
- DEMA 102307.63Bullish
- DEMA 202281.84Bullish
- DEMA 502274.08Bullish
- TEMA 102309.54Bullish
- TEMA 202311.56Bullish
- TEMA 50N/AN/A
- MACD26.82Bullish
- ADX35.27Strong Trend
- IndicatorValueSignal
- RSI62.35Neutral
- CCI75.46Neutral
- ROC 90.52Bullish
- ROC 149.08Bullish
- ROC 254.99Bullish
- Stoch K82.19Overbought
- Stoch D80.36Overbought
- IndicatorValueSignal
- BB Upper2381.46Neutral
- BB Middle2221.44Neutral
- BB Lower2061.42Neutral
- ATR53.19Low Volatility
- IndicatorValueSignal
- MFI76.98Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 102205.87Bullish
- SMA 202213.69Bullish
- SMA 502171.78Bullish
- SMA 1002055.31Bullish
- SMA 2002190.99Bullish
- EMA 102239.47Bullish
- EMA 202225.14Bullish
- EMA 502176.63Bullish
- EMA 1002147.61Bullish
- EMA 2002162.84Bullish
- DEMA 102266.46Bullish
- DEMA 202246.64Bullish
- DEMA 502245.68Bullish
- DEMA 1002149.60Bullish
- DEMA 2002145.21Bullish
- TEMA 102295.89Bearish
- TEMA 202235.07Bullish
- TEMA 502293.42Bearish
- TEMA 1002210.06Bullish
- TEMA 2002076.19Bullish
- MACD17.65Bullish
- ADX24.22Weak Trend
- IndicatorValueSignal
- RSI56.84Neutral
- CCI92.33Neutral
- ROC 142.40Bullish
- ROC 25-2.36Bearish
- Stoch K84.13Overbought
- Stoch D82.31Overbought
- IndicatorValueSignal
- BB Upper2341.05Neutral
- BB Middle2213.69Neutral
- BB Lower2086.34Neutral
- ATR85.64Low Volatility
- IndicatorValueSignal
- MFI81.44Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 202050.73Bullish
- SMA 502227.36Bearish
- EMA 202150.41Bullish
- EMA 502164.32Bullish
- DEMA 202159.97Bullish
- DEMA 502177.88Bullish
- TEMA 202220.33Bearish
- TEMA 502076.50Bullish
- MACD19.05Bullish
- ADX22.35Weak Trend
- IndicatorValueSignal
- RSI51.88Neutral
- CCI-12.05Neutral
- ROC 1418.39Bullish
- ROC 25-5.41Bearish
- Stoch K59.10Neutral
- Stoch D63.10Neutral
- IndicatorValueSignal
- BB Upper2413.36Neutral
- BB Middle2050.73Neutral
- BB Lower1688.10Neutral
- ATR165.18High Volatility
- IndicatorValueSignal
- MFI91.29Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 62097.00Bullish
- SMA 122225.04Bearish
- SMA 242198.26Bullish
- EMA 62149.31Bullish
- EMA 122157.60Bullish
- EMA 242048.85Bullish
- DEMA 62140.25Bullish
- DEMA 122182.20Bullish
- DEMA 242355.64Bearish
- TEMA 62168.31Bullish
- TEMA 122089.54Bullish
- TEMA 242261.84Bearish
- MACD399.32Bearish
- ADX38.12Strong Trend
- IndicatorValueSignal
- RSI58.56Neutral
- CCI82.41Neutral
- ROC 2543.86Bullish
- ROC 50296.95Bullish
- Stoch K51.68Neutral
- Stoch D65.29Neutral
- IndicatorValueSignal
- BB Upper2589.01Neutral
- BB Middle2234.78Neutral
- BB Lower1880.54Neutral
- ATR341.93Low Volatility
- IndicatorValueSignal
- MFI70.75Neutral